Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $35.00

Arcutis Biotherapeutics (NASDAQ:ARQT) had its price objective boosted by TD Cowen from $30.00 to $35.00 in a report published on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other brokerages have also issued reports on ARQT. Zacks Research lowered shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. HC Wainwright boosted their target price on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a report on Thursday. Needham & Company LLC increased their price target on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday. The Goldman Sachs Group lifted their price target on shares of Arcutis Biotherapeutics from $19.00 to $29.00 and gave the company a “neutral” rating in a research report on Thursday, October 30th. Finally, Mizuho increased their price objective on Arcutis Biotherapeutics from $32.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, November 28th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $32.14.

Arcutis Biotherapeutics Price Performance

NASDAQ:ARQT opened at $26.97 on Thursday. Arcutis Biotherapeutics has a one year low of $11.86 and a one year high of $31.77. The stock has a market cap of $3.35 billion, a PE ratio of -192.63 and a beta of 1.70. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.28 and a current ratio of 3.50. The stock has a 50 day moving average price of $27.24 and a 200 day moving average price of $23.86.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its earnings results on Wednesday, February 25th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.10. Arcutis Biotherapeutics had a negative return on equity of 11.01% and a negative net margin of 4.29%.The company had revenue of $129.50 million during the quarter, compared to analysts’ expectations of $110.79 million. Equities research analysts expect that Arcutis Biotherapeutics will post -1.33 EPS for the current fiscal year.

Insider Activity

In related news, insider Todd Watanabe sold 19,833 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $25.50, for a total value of $505,741.50. Following the completion of the sale, the insider owned 721,306 shares in the company, valued at approximately $18,393,303. This trade represents a 2.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry Todd Edwards sold 2,052 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $25.50, for a total value of $52,326.00. Following the completion of the sale, the insider directly owned 148,865 shares in the company, valued at approximately $3,796,057.50. The trade was a 1.36% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 124,656 shares of company stock worth $3,312,365 in the last three months. 9.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several hedge funds have recently bought and sold shares of ARQT. Perpetual Ltd boosted its holdings in Arcutis Biotherapeutics by 7,534.3% during the 3rd quarter. Perpetual Ltd now owns 2,024,606 shares of the company’s stock valued at $38,164,000 after acquiring an additional 1,998,086 shares during the period. Suvretta Capital Management LLC lifted its position in shares of Arcutis Biotherapeutics by 14.2% during the fourth quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock worth $347,435,000 after purchasing an additional 1,486,000 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Arcutis Biotherapeutics by 10.3% during the third quarter. Jennison Associates LLC now owns 12,254,119 shares of the company’s stock worth $230,990,000 after purchasing an additional 1,144,714 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its stake in shares of Arcutis Biotherapeutics by 12.4% in the second quarter. Frazier Life Sciences Management L.P. now owns 9,874,511 shares of the company’s stock valued at $138,441,000 after purchasing an additional 1,089,227 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Arcutis Biotherapeutics by 1,228.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,166,348 shares of the company’s stock valued at $33,872,000 after purchasing an additional 1,078,546 shares in the last quarter.

More Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Solid Q4 results and revenue beat — Arcutis reported a robust Q4 with revenue growth and a GAAP EPS beat, driven by Zoryve adoption; the quarter and raised guidance underpin the bullish view on commercial execution. Arcutis Biotherapeutics surges on earnings beat, raised guidance
• Positive Sentiment: Multiple analyst price-target increases — Needham, TD Cowen and Guggenheim raised targets (to the mid-$30s) and maintain buy ratings, signaling analyst confidence in growth and creating upside narrative for the stock. Benzinga coverage of analyst price-target changes
• Positive Sentiment: Bull case coverage highlights pipeline and label-expansion catalysts — Recent analyst and media pieces emphasize Zoryve market leadership, operating leverage and upcoming pediatric/label catalysts that could support longer-term upside. Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case
• Neutral Sentiment: Investor presentation scheduled — Management will present at TD Cowen’s healthcare conference next week, giving investors an opportunity for updated guidance/visibility; this is a near-term catalyst but not an immediate earnings event. Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
• Neutral Sentiment: Broad coverage and transcripts available — Earnings call transcript and multiple recaps give investors transparency into execution and guidance; this helps short- and long-term assessment but is informational. Arcutis (ARQT) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Near-term EPS cuts by HC Wainwright — Despite maintaining a Buy and $34 target, HC Wainwright lowered Q2–Q4 2026 EPS estimates, which can temper short-term sentiment and provide a rationale for profit-taking after the post-earnings rally.
• Negative Sentiment: Mixed/unclear short-interest data — Recent short-interest reports appear inconsistent (zero/NaN entries), creating uncertainty about downside pressure from traders; unclear short-covering dynamics can add volatility.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.